Vaccines - Niger

Niger

The Vaccines market in Niger is anticipated to witness a considerable surge in revenue, projected to reach US$43.79m in 2024.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of -11.06%, ultimately leading to a market volume of US$24.37m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Vaccines market, reaching an impressive US$29,120.00m in 2024.
Niger is increasing its investment in vaccine research and development to combat diseases prevalent in the region.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Niger is on the rise due to several factors.

Customer preferences: Niger has a high infant mortality rate, and vaccines are crucial in reducing the number of deaths. As a result, parents in Niger are increasingly demanding vaccines to protect their children from preventable diseases such as measles, polio, and pneumonia.

Trends in the market: The vaccines market in Niger is growing, with an increasing number of children receiving vaccines. This growth can be attributed to the government's efforts to expand vaccination coverage and the support of international organizations such as UNICEF and the World Health Organization. Additionally, there has been an increase in the number of private sector companies supplying vaccines in Niger.

Local special circumstances: Niger is a landlocked country with a large rural population, which presents challenges in the distribution of vaccines. The country also faces security challenges in some regions, which can hinder the delivery of vaccines.

Underlying macroeconomic factors: Niger is one of the poorest countries in the world, and the government has limited resources to invest in healthcare. International aid plays a significant role in the provision of vaccines in Niger. The country's economy relies heavily on agriculture and mining, which can impact the availability of funds for healthcare initiatives.In conclusion, the vaccines market in Niger is expanding due to an increasing demand for vaccines to reduce infant mortality rates. The government and international organizations are playing a crucial role in expanding vaccination coverage, while the private sector is also contributing to the growth of the market. However, challenges such as the distribution of vaccines in rural areas and security concerns in some regions need to be addressed to ensure that vaccines reach all children in Niger.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.